HemoSphere Bio, the German company known for its small presence in blood therapies, proceeds in its goal to become the lead player in Hemophilia A treatment in Europe. Phase II clinical trials with the candidate Octomab were just concluded successfully.

HemoSphereBio is proud to announce the official opening of its new state-of-the-art production facility, marking a major milestone in the company’s growth and manufacturing capabilities.

HemoSphere Bio is excited to share promising new clinical data that supports the expansion of its ongoing clinical trials. This development marks a key step forward in advancing the company’s innovative therapeutic programs.

HemoSphereBio has reached a pivotal moment in its journey toward innovative therapies, announcing the submission of its Phase 1 clinical trial application.

HemoSphere Bio is pleased to announce an official partnership with Gerresheimer Germany, a leading provider of high-tech packaging solutions for the pharmaceutical and biotech industries.